It’s Been a Yawner of a Summer
Insights - The prettiest girl at the ball, Receptos (RCPT), went home with a handsome suitor this week. Celgene (CELG) is paying $7.2 billion, or $232 per … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Sleep Easy Healthcare Investors; Receptos has Been Bought
Insights - Healthcare investors can sleep easy tonight with one of 2015’s major unanswered questions now off the table. Celgene (CELG) will buy Receptos (RCPT) for $7.2 billion, or $232 in … Continue Reading
Read now
Yet Again, This Weekend May Be More Important Than This Week
Insights - Yet another choppy week for investors, and we’re going into another weekend in which decisions overseas will impact U.S. markets first thing on Monday. Greece submitted … Continue Reading
Read now
Cempra’s SOLITAIRE-IV Results are Just Months Away
Research - Cempra (CEMP) announced on Tuesday that enrollment in the phase III SOLITAIRE-IV trial is complete, and the company expects data from the study in the … Continue Reading
Read now
Marinus Pharmaceuticals Clears Up 2015Â Events – Sort Of
Research - PCDH19 female epilepsy is associated with low levels of allopregnanolone in the blood, a neurosteroid, hormone metabolite, and a positive allosteric modulator of the GABAa receptor.
Premium
Celgene Recommits to Cancer Collaboration with Epizyme
Insights - Just in front of its option deadline, Celgene (CELG) has re-upped on an existing research and discovery collaboration with Epizyme (EPZM), a developer of targeted cancer … Continue Reading
Read now
Once Scorned, Horizon Makes Hostile Bid for Depomed
Insights - Horizon Pharma (HZNP) has gone hostile in its attempt to acquire Depomed (DEPO), offering $29.25 in HZNP stock, or $3 billion, for the smaller specialty … Continue Reading
Read now